Development of a 12-Valent HPV L1 Virus-like Particle Vaccine Using an Enhanced Baculovirus Expression System

Area of Science:

• Vaccinology
• Molecular Virology
• Biotechnology

Background:

• Cervical cancer, caused by high-risk human papillomaviruses (HPVs), is a leading global cancer in women.
• Current prophylactic HPV vaccines are effective but limited by high costs and concentrated manufacturing.
• Suboptimal global vaccine use disproportionately affects low- and middle-income countries.

Purpose of the Study:

• To establish a cost-effective multivalent HPV virus-like particle (VLP) vaccine platform.
• To enhance antigen yield and reduce manufacturing costs for improved vaccine affordability and availability.
• To develop a 12-valent HPV VLP vaccine using an enhanced baculovirus expression vector system.

Main Methods:

• Optimized expression cassettes and insect cell culture for enhanced productivity of 12 HPV L1 genotypes.
• Developed a scalable purification process using ion-exchange and adsorption chromatography for high-purity VLPs.
• Assessed immunogenicity in a murine model, comparing HPV type-specific IgG responses to a licensed 9-valent HPV vaccine.

Main Results:

• Assembled 12-valent VLPs demonstrated structural stability and correct antigenicity via biophysical and immunochemical analyses.
• In vivo studies in mice induced strong, serotype-specific IgG responses.
• Immune responses were comparable or superior to those elicited by the licensed 9-valent HPV vaccine.

Conclusions:

• The enhanced baculovirus expression vector system provides a versatile and economically sustainable platform for next-generation HPV vaccine production.
• This technology offers a promising strategy for reducing vaccine manufacturing costs.
• Improved global access to HPV vaccines, particularly in high-burden regions, is a key potential outcome.